Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide-Reference-Cited by-同舟云学术

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide

Published:2020-11-07 Issue:1 Volume:100 Page:169-180
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Zhao Jiao-Yu,Liu Si-Ning,Xu Lan-Ping,Zhang Xiao-Hui,Wang Yu,Chen Yu-Hong,Liu Kai-Yan,Huang Xiao-Jun,Mo Xiao-Dong^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-04273-2.pdf

Reference67 articles.

1. Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang J, Wu D, Zhou D, Zou P, Liu K, Huang X (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11(1):33–33. https://doi.org/10.1186/s13045-018-0564-x

2. Deeg HJ, Henslee-Downey PJ (1990) Management of acute graft-versus-host disease. Bone Marrow Transplant 6(1):1–8

3. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550–1561. https://doi.org/10.1016/s0140-6736(09)60237-3

4. Garnett C, Apperley JF, Pavlu J (2013) Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol 4(6):366–378. https://doi.org/10.1177/2040620713489842

5. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF (2001) Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27(10):1059–1064. https://doi.org/10.1038/sj.bmt.1703032

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults;European Respiratory Journal;2024-03

2. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis;Bone Marrow Transplantation;2024-02-24

3. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease;Expert Review of Clinical Immunology;2023-08-22

4. Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation;Blood Science;2022-12-07

5. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis;Frontiers in Immunology;2022-08-04